Combining medication with a leading behavioral change engine to drive the adoption of healthy habits addresses patient demand
The Rosenstock Phase 2 in type 2 diabetes assigned 281 adults T2D, BMI 25 to retatrutide across multiple dose tiers, an active GLP-1 mono-agonist comparator, or placebo
New Research Into How Oral GLP-1s Act in the Brain A study published in the journal Nature on 6 May 2026 offered a further dimension to the oral versus injectable debate
The MindBody GLP-1 System represents the culmination of years of research into the synergistic effects of natural ingredients on appetite and metabolism, said Lisa Barnes, Vice President of Research and Development and Regulatory at LifeVantage
Thus, interventions that are effective at treating obesity will most likely be those that target multiple receptors in complementary neurocircuits and regulate energy balance
Pediatrics 2001;108:776-89